Romosozumab in Postmenopausal Women with Low Bone Mineral Density

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases

(2012) Hua Zhu Ke et al.   ENDOCRINE REVIEWS

Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover

(2011) Antoon H van Lierop et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways

(2010) Carola Krause et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH